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Abstract
There is increasing interest in the development of multiple sclerosis (MS) biomarkers that reflect central nervous system tis-
sue injury to determine prognosis. We aimed to assess the prognostic value of kinesin superfamily motor protein KIF5A in 
MS by measuring levels of KIF5A in cerebrospinal fluid (CSF) combined with analysis of single nucleotide polymorphisms 
(SNPs; rs12368653 and rs703842) located within a MS susceptibility gene locus at chromosome 12q13–14 region. Enzyme-
linked immunosorbent assay was used to measure KIF5A in CSF obtained from two independent biobanks comprising 
non-inflammatory neurological disease controls (NINDC), clinically isolated syndrome (CIS) and MS cases. CSF KIF5A 
expression was significantly elevated in progressive MS cases compared with NINDCs, CIS and relapsing–remitting MS 
(RRMS). In addition, levels of KIF5A positively correlated with change in MS disease severity scores (EDSS, MSSS and 
ARMSSS), in RRMS patients who had documented disease progression at 2-year clinical follow-up. Copies of adenine risk 
alleles (AG/AA; rs12368653 and rs703842) corresponded with a higher proportion of individuals in relapse at the time of 
lumbar puncture (LP), higher use of disease-modifying therapies post LP and shorter MS duration. Our study suggests that 
CSF KIF5A has potential as a predictive biomarker in MS and further studies into the potential prognostic value of analysing 
MS susceptibility SNPs should be considered.
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Introduction
Multiple sclerosis (MS) is an immune-mediated inflam-
matory and neurodegenerative disease, presenting with 
clinical relapses [associated with inflammatory lesions 
within the central nervous system (CNS)], and/or progres-
sive neurological decline (associated with axonal loss and 
neurodegeneration) [1]. Due to the complex, multifaceted 
pathophysiology of MS, predicting prognosis at disease 
onset, which impacts on the choice of disease-modifying 
therapy (DMT), remains challenging and imprecise. Current 
measures of disease activity include MRI analysis of lesion 
load and relapse rates, which reflect inflammatory aspects 
of the disease but do not correlate well with progressive 
disability [2]. Consequently, there is increasing interest in 
the development of MS fluid biomarkers that reflect CNS tis-
sue injury to determine prognosis and/or monitor efficacy of 
treatment. Both radiological and post-mortem human tissue 
studies have already revealed axonal injury and loss in MS 
are closely linked to disability accumulation [1, 3, 4], thus 
axonal proteins may represent a potential avenue for reliable 
biomarker development.
Neurofilaments (NF) are major structural proteins of the 
axonal cytoskeleton, whose phosphorylation improves struc-
tural stability [5]. NFs in the cerebrospinal fluid (CSF) are 
considered to be a reliable marker of neuroaxonal damage 
[6] and many studies have highlighted NF-light (NF-L) as 
a prognostic and treatment-responsive biomarker in MS [7, 
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8]. However, multi-centre validation of these findings and 
determining age-dependent cut-off values for NF-L expres-
sion are required before consideration in clinical practice [9].
Both hypo- and hyper- phosphorylation of NFs within 
axons are recognised as pathological hallmarks of MS [10, 
11] and it is believed dysregulated axonal transport could be 
a catalyst for aberrant protein phosphorylation and accumu-
lation [12, 13]. The majority of anterograde axonal transport 
is governed by kinesin superfamily motor proteins (KIFs) 
[14]. KIF5A is the main kinesin subtype involved in antero-
grade transport of phosphorylated NFs [12, 15].
In humans, a missense mutation within the KIF5A gene 
(N256S) causes an autosomal dominant form of hereditary 
spastic paraplegia, known as SPG10. This disease is char-
acterised pathologically by axonal loss in the corticospinal 
tract [16]. Another missense mutation in the KIF5A gene 
has been linked to Charcot-Marie-Tooth disease (CMT-2A); 
an inherited peripheral axonopathy [17]. More recently, hot-
spot mutations in KIF5A have also been shown to cause 
familial amyotrophic lateral sclerosis (ALS) [18]. In addition 
to point mutations, several genome-wide association studies 
(GWAS) have identified single nucleotide polymorphisms 
(SNPs; rs12368653, rs703842, rs10431552, rs10877013 and 
rs6581155) at chromosome 12q13–14. This region spans 
17 candidate genes, including KIF5A that confer suscep-
tibility to MS [19–21]. Our previous studies have found 
reduced KIF5A expression in post-mortem MS brain; lev-
els of which appear to be influenced by MS susceptibility 
SNPs (rs12368653 and rs703842) [22, 23]. In addition, we 
have shown that these MS susceptibility SNPs are linked 
to increased markers of axonal injury in MS tissue [23]. In 
this study, we aimed to determine the prognostic value of 
measuring CSF KIF5A levels in conjunction with the pres-
ence of MS susceptibility SNPs (rs12368653 and rs703842) 
in people with MS.
Methods
Patient cohort and CSF sampling
CSF samples were obtained from two independent biobanks 
(Bristol and Cardiff). The Bristol cohort was used for analy-
sis of KIF5A protein in CSF from people with MS and idi-
opathic intracranial hypertension (IIH). Ethical approval was 
received from the South West—Frenchay Research Ethics 
Committee (REC: 09/H0107/72) for lumbar puncture (LP) 
collection of CSF from patients with suspected CNS inflam-
mation from neurology clinics based at Southmead Hospi-
tal, Bristol, with written consent. Patients with a diagnosis 
of relapsing–remitting MS (RRMS; n = 38), primary pro-
gressive MS (PPMS; n = 6) or secondary progressive MS 
(SPMS; n = 3), at the time of LP, were included in the study, 
as classified by revised 2017 McDonald criteria [24]. CSF 
was removed from patients with IIH for therapeutic relief 
and collected as a waste product, as per local REC recom-
mendations. No clinical data was collected on IIH patients. 
These samples served as a non-inflammatory neurological 
disease control (NINDC n = 49). CSF was processed within 
2hrs of collection, centrifuged at 3000×g for 10 min at room 
temperature and the supernatant separated into 300 µL ali-
quots, before storage at − 80 °C.
The Cardiff cohort had comprehensive clinical data avail-
able for samples and paired DNA samples for analysis of 
patient genotype. This cohort was used to analyse KIF5A 
in CIS and MS, in relation to a range of independent cohort 
variables including genotype. CSF and DNA samples 
were requested and received from the Welsh Neuroscience 
Research Tissue Bank (University Hospital of Wales, Car-
diff, UK; REC: 14/WA/0073). Patients with a diagnosis of 
clinically isolated syndrome (CIS; n = 27), RRMS (n = 67), 
PPMS (n = 6) or SPMS (n = 5), according to contemporary 
diagnostic criteria at the time of LP for suspected neuroin-
flammation, were included in the study. No patients were 
receiving DMT or steroid therapy before LP. CSF was pro-
cessed within 1 h of collection, centrifuged at 4400×g for 
10 min at 4 °C and the supernatant separated into 300 µL 
aliquots, before storage at − 80 °C.
Power calculation for SNP genotype and patient 
genotyping
A power calculation to determine required samples sizes 
was performed prior to this study. The power analysis 
was based on clinically significant differences detected in 
KIF5A protein expression between MS patients grouped by 
rs703842 SNP alleles (GG vs AA) [23]. In this study the 
calculated standardised difference in KIF5A expression was 
0.87. Using two-sample inference of means, case numbers 
required to detect similar change in KIF5A protein expres-
sion at 0.80 power and 0.05 significance was 22 patients per 
group [25].
Within the Cardiff cohort, most participants who had 
donated CSF had already been genotyped for rs703842 and 
rs12368653. For both SNPs, adenine (A) represents the MS 
risk allele, with the alternative allele being guanine (G). 
gDNA was provided for 18 cases without genotype data 
and an additional 6 positive control genotype samples for 
rs703842 (AA, AG and GG) and rs12368653 (AA, AG and 
GG). 5 µL of diluted gDNA (2 ng/µL) was added in dupli-
cate to a  MicroAmp® Fast Optical 96-Well Reaction Plate 
(ThermoFisher Scientific), including positive control sam-
ples and no template controls. 20 × TaqMan® SNP Genotyp-
ing Assays (rs12368653 or rs4646536 (proxy for rs703842; 
linkage disequilibrium r2 = 1 [20]), ThermoFisher Scien-
tific) were diluted in DNase-free  H2O and 2 × qPCRBIO 
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Genotyping Mix Hi-ROX (PCR Biosystems) and added 
to the appropriate samples wells to achieve a total volume 
of 20 µL. Genotyping was performed on a StepOnePlus™ 
Real-Time PCR system with clustering algorithm software 
(ThermoFisher Scientific), on a FAST ramp speed.
Enzyme‑linked immunosorbent assay (ELISA)
Levels of KIF5A protein in CSF were detected using com-
mercially validated human ELISA kit for KIF5A (BT-Labs; 
E2780Hu; sensitivity 4.93 ng/L), as per manufacturers’ 
instructions. The kit had an intra- and inter-assay coeffi-
cient of 8% and 10% respectively (n = 3). CSF was defrosted 
shortly before the assays and repeated cycles of thawing and 
re-freezing avoided. Protein standards, samples and blanks 
were run in duplicate. 40 µL of undiluted CSF was loaded 
per well, respectively. Plates included the following posi-
tive and negative controls; MS white matter brain homoge-
nate, blank (sample diluent and PBS) and biotin antibody 
negative. Protein absorbance was read at 450 nm using a 
FLUOstar OPTIMA plate reader 213 (BMG labtech, Ayles-
bury, BUCKS, UK). The associated OPTIMA software 
programme was used to interpolate sample protein concen-
trations from the respective standard curves generated by 
serially diluting kit protein standards.
Statistics
Frequency distributions were examined using the χ2 con-
tingency test. Data normality was tested using the Shap-
iro–Wilk test. Where clinical data was skewed, the median 
was used for data analysis. Assessment and appropriate 
removal of outliers from KIF5A ELISA data was per-
formed using the mean ± 2 × standard deviation. Univariate 
protein analysis was performed using GraphPad Prism5™ 
(GraphPad Software Inc.; San Diego, USA). Parametric one-
way ANOVA with post-hoc Bonferroni, or non-parametric 
Kruskal–Wallis with post-hoc Dunn’s test or Spearman’s 
rank correlation coefficient, as appropriate, was used to ana-
lyse KIF5A protein expression, in relation to disease pheno-
type and other independent cohort variables. For univariate 
tests, values of p < 0.05 were considered statistically sig-
nificant. Multiple regression analysis was performed using 
STATA v12 (StataCorp LLC; Texas, USA). For multivariate 
analysis KIF5A protein levels was the dependent variable 
which was analysed against several independent cohort vari-
ables. Where necessary, data were transformed to normality 
before regression analysis. For multivariate analysis, an α 
0.05 cut-off level was used to determine statistical signifi-
cance and Bonferroni correction applied to allow for multi-
ple testing and Type I errors.
Results
Cohort variances
Within the Bristol MS cohort, CSF sample storage duration 
ranged from 1 to 10 years (mean 5 years ± 2). MS cases 
ranged in age from 21 to 64 years (mean 41 years ± 12; 
n = 47) (Table 1). There was a significant difference in the 
average age of the RRMS cohort (mean 38 years ± 11) com-
pared with the progressive MS cohort (PPMS and SPMS; 
mean 52 years ± 7) (p < 0.001; Supplementary Fig. 1). As 
a result of ethical constraints, no data was available on age 
or sex for IIH cases. Within the Cardiff cohort, sample stor-
age ranged from 1 to 13 years (mean 6 years ± 4). Individu-
als ranged in age from 17 to 70 years (mean 41 years ± 12; 
n = 106). The MS subtype was unknown in one case, which 
excluded it from further analysis (Table 2). Like Bristol, 
there was a significant difference in the average age of 
patients with progressive MS (PPMS and SPMS; mean 55 
years ± 9), compared with CIS (37 years ± 12) and RRMS 
(mean 40 years ± 10) (p < 0.001; Supplementary Fig. 2).
CSF KIF5A is elevated in MS CSF compared 
with non‑inflammatory neurological disease control
The Bristol cohort was used to determine differences in 
KIF5A CSF levels between NINDC (IIH) and MS. KIF5A 
levels were significantly higher in RRMS and progressive 
MS compared with IIH (p < 0.05; Fig. 1). Multivariate analy-
sis with Bonferroni correction for type I errors, confirmed 
the finding with progressive MS (p < 0.01) but not RRMS 
p < 0.05; Table 3a). In addition, it showed no effect of IIH 
or MS sample storage duration on CSF KIF5A expres-
sion (p = 0.26; Table 3a). No data was available for age or 
sex of IIH but within the MS cohort, there was no effect 
of age (p = 0.46), sex (p = 0.48) or sample storage duration 
(p = 0.15) on MS CSF KIF5A expression (n = 47; Table 3b).
Table 1  Clinical characteristics of the Bristol cohort
IIH idiopathic intracranial hypertension, PPMS primary progres-
sive multiple sclerosis, RRMS relapsing–remitting multiple sclerosis, 
SPMS secondary progressive multiple sclerosis
Bristol cohort variables n
Sample storage [mean ± SD (range)] 96 [5 years ± 2 (1–10)]
Sex (F/M) 31/16
IIH 49
RRMS [mean age ± SD (range)] 38 [38 years ± 11(21–64)]
PPMS [mean age ± SD (range)] 6 [52 years ± 5 (42–57)]
SPMS [mean age ± SD (range)] 3 [52 years ± 11 (40–61)]
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CSF KIF5A expression is significantly elevated 
in progressive MS compared with CIS and RRMS
Detailed clinical documentation for Cardiff cohort CSF 
samples was used to analyse differences in KIF5A expres-
sion between CIS and MS subtypes. Four outliers within the 
KIF5A data were removed from cohort multivariate analy-
sis. In univariate analysis, levels of KIF5A detected in CSF 
were significantly higher in patients with progressive MS 
compared with RRMS (p < 0.01; Fig. 2). This effect was 
confirmed in multivariate analysis (p < 0.01), which also 
revealed a significant difference in levels of CSF KIF5A 
between CIS and progressive MS samples when account-
ing for additional independent cohort variables (p < 0.01; 
Table 4). There was no effect of age (p = 0.94), sex (p = 0.74) 
or sample storage duration (p = 0.08) on KIF5A expression 
(Table 4). Initial analysis also showed levels of KIF5A in 
MS CSF were significantly higher in patients who were in 
relapse at time of LP (p < 0.01; Fig. 3) but the finding was 
not supported in the multivariate model (p = 0.27; Table 4). 
In multivariate analysis, no significant associations were 
found with MS duration, first inter-attack interval, multi-
ple sclerosis severity scale (MSSS) and age-related MSSS 
(ARMSSS; Table 4). When studying KIF5A expression 
in relation to disease severity scores (EDSS, MSSS and 
ARMSS) over 2-year follow-up in the RRMS cohort there 
was no significant correlation (n = 67). However, when ana-
lysing RRMS cases that showed progression over 2-year 
follow-up there was a significant positive correlation with 
KIF5A levels (n = 35; Fig. 4). The mean and median follow-
up assessment interval was 24 months (range 13–40 months; 
n = 35). Cases were excluded from analysis where initial 
EDSS assessment was more than 4 months post LP (n = 10).
MS risk SNPs are associated with MS disease activity
Within the Cardiff cohort, we investigated associations 
between CSF KIF5A and SNPs (rs703842 and rs12368653; 
both risk allele A) at chromosome 12q13–14 that are linked 
to MS susceptibility. Multivariate analysis showed a sig-
nificant effect of patient rs703842 genotype (AA vs AG) on 
CSF KIF5A levels, alongside disease subtype and a range 
of independent cohort variables (p < 0.05; Table 4). There 
was no significant difference in patient age between SNP 
susceptibility alleles [rs703842 (p = 0.20) and rs12368653 
(p = 0.07); n = 106, Supplementary Fig. 3]. There was no 
significant difference in MS duration (measured from symp-
tom onset) in patients homozygous for rs703842 risk SNP 
AA vs GG (p = 0.09; Fig. 5a) but a significantly shorter MS 
Table 2  Clinical characteristics of the Cardiff cohort
AA homozygous adenine, AG heterozygous adenine/guanine, 
ARMSSS age-related multiple sclerosis severity scale, Cau Caucasian, 
CIS clinically isolated syndrome, DMT disease-modifying therapy, 
EDSS expanded disability status scale of Kurtze, GG homozygous 
guanine, LP lumbar puncture, MSSS multiple sclerosis severity scale, 
PPMS primary progressive multiple sclerosis, RRMS relapsing remit-
ting multiple sclerosis, SPMS secondary progressive multiple sclero-
sis, WB white British
Cardiff cohort variables n





 CIS [mean age ± SD (range)] 27 [37 years ± 12 (17–61)]
 RRMS [mean age ± SD (range)] 67 [40 years ± 10 (26–70)]
 PPMS [mean age ± SD (range)] 6 [54 years ± 10 (38–68)]





















First inter-attack interval [median 
(range)]
66 [2 years (0.1–45.4)]
MS duration [median (range)] 84 [2 years (0.1–45.9)]







Fig. 1  KIF5A levels are elevated in MS CSF compared with non-
inflammatory neurological disease control (NINDC) in the Bris-
tol cohort. Levels of KIF5A measured by ELISA are significantly 
increased in RRMS (n = 38) and progressive MS (n = 9) when com-
pared to NINDC (IIH) (n = 48). Values represented as mean ± SEM. 
Statistical test used: one-way ANOVA with post-hoc Bonferroni; 
*p < 0.05. IIH idiopathic intracranial hypertension, KIF kinesin 
superfamily motor protein, RRMS relapsing–remitting multiple scle-
rosis
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duration in patients homozygous for rs12368653 risk SNP 
AA vs GG (p < 0.05; Fig. 5b). Combining both genotypes 
showed no significant difference in MS duration in patients 
homozygous for both SNPs (AA/AA) compared to those 
with no copies (GG/GG; p = 0.06; Fig. 5c). There was no 
significant difference in first inter-attack interval in patients 
homozygous for MS risk SNPs rs703842 [p = 0.99, n = 64) 
and rs12368653 (p = 0.55, n = 65); Supplementary Fig. 4]. 
However, when each allele subset (GG, AG, AA) was nor-
malised to correct for allele population frequency, only 
patients with copies of risk alleles (AG and AA) were docu-
mented as being in active relapse at the time of LP (rs703842 
χ2 = 9.85 and rs12368653 χ2 = 9.93; p < 0.01, n = 62; Fig. 6). 
In addition, a significantly higher percentage of patients in 
the cohort with copies of risk alleles (AG and AA) received 
a DMT post LP, compared to those without copies (GG) 
(rs703842 χ2 = 20.69 and rs12368653 χ2 = 19.31; p < 0.001, 
n = 88; Fig. 7).
Discussion
Novel prognostic biomarkers for MS are lacking. Proteins 
linked to inflammation such as myelin basic protein, have 
been analysed in CSF as a measure of disease activity but 
lack disease specificity. Axonal proteins are currently being 
studied as a more accurate reflection of neuronal damage and 
disease progression [26].
In this study, we have found significantly higher levels 
of KIF5A expression in CSF from progressive MS cases, 
validated in two independent CSF biobanks. In samples 
from the Bristol cohort, KIF5A was significantly elevated 
in progressive MS CSF compared with NINDC (IIH). One 
limitation of the Bristol cohort is the absence of clinical data 
for IIH, which restricts the multivariate analysis. However, it 
has the advantage of being a single NINDC diagnosis group, 
whereas other MS biomarker studies have heterogenous con-
trol populations [27, 28].
KIF5A is a neuronally enriched motor protein linked to 
anterograde axonal transport of various intracellular car-
goes including phosphorylated NFs [12, 15]. Mouse models 
have shown KIF5A knockout is neonatal lethal. Post-natal 
Table 3  Multivariate analysis of IIH sample storage and MS cohort variables on KIF5A expression in the Bristol cohort
Bonferroni correction to the required αλπηα 0.05 cut-off for significance has been applied. Significant associations highlighted in bold
IIH idiopathic intracranial hypertension, KIF kinesin superfamily motor protein, MS multiple sclerosis, RRMS relapsing–remitting multiple scle-
rosis
a
Protein n Variables Coefficient Standard error t p value 95% Confidence 
intervals
KIF5A (ng/mL) 96 IIH vs RRMS 0.040 0.017 − 2.33 0.022 0.006 0.074
IIH vs progressive MS 0.076 0.025 3.03 0.003 0.026 0.125
RRMS vs progressive MS 0.036 0.027 1.34 0.184 − 0.017 0.088
IIH and MS storage time 0.004 0.003 1.13 0.260 − 0.003 0.011
b
Protein n Variables Coefficient Standard error t p value 95% confidence 
intervals
KIF5A (ng/mL) 47 MS storage time 0.006 0.004 1.47 0.150 − 0.002 0.015
MS age − 0.001 0.001 − 0.74 0.462 − 0.003 0.001
MS sex − 0.021 0.029 − 0.72 0.477 − 0.078 0.037
Fig. 2  CSF KIF5A levels are elevated in progressive MS in the Car-
diff cohort. KIF5A protein expression in cerebrospinal fluid sam-
ples were detected using ELISA. There was a significant increase 
in KIF5A expression in progressive MS cases (n = 10) compared 
with RRMS (n = 63) but not CIS (n = 26). Values represented as 
mean ± SEM. Statistical test used: one-way ANOVA with post-hoc 
Bonferroni; **p < 0.01. CIS clinically isolated syndrome, KIF5A 
kinesin superfamily motor protein 5A, RRMS relapsing–remitting 
multiple sclerosis
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targeting of the gene resulted in age-dependent sensory neu-
rodegeneration and hind limb paralysis. This is attributed to 
NF accumulation in the cell body and axonal loss [12]. NF-L 
has been studied as a potential prognostic biomarker in MS 
and levels correlate well with markers of neuroinflammation 
including acute relapse and lesion load [27, 29]. However, 
there is confounding evidence on the utility of NF-L as a 
predictor of MS disability accumulation [30, 31].
In the Cardiff cohort, KIF5A was significantly elevated in 
CSF from progressive MS compared with RRMS and CIS in 
multivariate analysis. CSF KIF5A levels were significantly 
higher in patients who were in relapse at time of LP com-
pared to patients who were not. This was not replicated in 
multivariate analysis, which may be due to the number of 
cases in relapse being underpowered. It is likely that acute 
inflammation during relapse could cause a higher influx of 
KIF5A into the CSF due to disruption at the blood brain 
barrier. This has also been found in studies examining NF-L 
as a marker of neuronal damage in MS [8].
Our finding of higher KIF5A levels in progressive MS 
patients compared with RRMS suggest CSF KIF5A levels 
could be predictive for underlying axonal loss and progres-
sive disability. This is further supported by our data show-
ing levels of KIF5A positively correlate with change in 
MS disease severity scores (EDSS, MSSS and ARMSSS), 
in RRMS patients who have documented disease pro-
gression at 2-year clinical follow-up. In progressive MS, 
patients become increasingly disabled over time as a result 
of axonal loss [3]. It is believed early axonal transport 
deficits that cause processes such as reduced transport of 
mitochondria and decreased ATP availability could initiate 
axonal damage and loss in MS [13]. One explanation for 
transport abnormalities could be reduced availability of 
KIFs. We have previously shown reduced KIF5A protein 
expression in MS white matter that inversely correlated 
with levels of APP and NFs [23], which are commonly 
found in axonal spheroids [10, 32]. Inflammatory media-
tors present in MS pathogenesis could also disrupt axonal 
Table 4  Multiple regression analysis of KIF5A within the Cardiff cohort
Bonferroni correction to the required αλπηα 0.05 cut-off for significance has been applied. Significant associations highlighted in bold
AA homozygous adenine, AG heterozygous adenine/guanine, CIS clinically isolated syndrome, ARMSSS age-related multiple sclerosis severity 
score, GG homozygous guanine, EDSS expanded disability status score, KIF kinesin superfamily motor protein, LP lumbar puncture, MSSS mul-
tiple sclerosis severity score, RRMS relapsing–remitting multiple sclerosis
Protein n Variables Coefficient Standard error t p value 95% Confidence 
intervals
KIF5A (ng/mL) 101 CIS vs RRMS 0.081 0.058 1.39 0.176 − 0.039 0.200
CIS vs progressive MS 0.333 0.088 3.82 0.001 0.154 0.515
RRMS vs progressive MS 0.254 0.077 3.29 0.003 0.095 0.413
102 Age at LP − 0.005 0.004 − 1.18 0.250 − 0.013 0.004
102 Storage time − 0.012 0.008 − 1.59 0.125 − 0.028 0.004
102 Sex 0.026 0.058 0.45 0.654 − 0.094 0.147
102 rs703842 GG vs AA 0.173 0.157 1.10 0.281 − 0.151 0.497
rs703842 AG vs AA 0.151 0.060 2.53 0.019 0.028 0.275
102 rs12368653 GG vs AA 0.023 0.090 0.26 0.799 − 0.163 0.210
rs12368653 AG vs AA 0.063 0.072 0.87 0.391 − 0.085 0.211
70 MSSS 0.015 0.017 0.91 0.371 − 0.020 0.051
83 ARMSSS − 0.030 0.022 − 1.35 0.191 − 0.765 0.016
60 Relapsing at LP − 0.139 0.124 − 1.12 0.273 − 0.394 0.116
67 First inter-attack interval 0.000 0.004 0.12 0.904 − 0.007 0.008
Fig. 3  CSF KIF5A levels are elevated in MS relapse in the Cardiff 
cohort. KIF5A levels in MS CSF detected using ELISA are signifi-
cantly higher in patients relapsing at the time of LP (n = 5) compared 
to those who are not (n = 54). Values expressed as mean ± SEM. Sta-
tistical test used: two-tailed T-test; **p < 0.01. KIF5A kinesin super-
family motor protein 5A, LP lumbar puncture
Journal of Neurology 
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Fig. 4  Levels of CSF KIF5A 
positively correlate with 
measures of disease severity in 
2-year follow-up of relapsing–
remitting patients within Cardiff 
cohort (n = 35). Levels of CSF 
KIF5A measured by ELISA 
significantly correlate with 
change in EDSS (a), MSSS 
(b) and ARMSSS (c) score as 
recorded from LP and average 
24-month follow-up (range 
13–40 months). KIF5A values 
expressed as mean. Statisti-
cal test used: non-parametric 
Spearman’s rank correlation 
coefficient, *p < 0.05. ARMSSS 
age-related multiple sclerosis 
severity score, EDSS expanded 
disability status score, KIF5A 
kinesin superfamily motor 
protein 5A, MSSS multiple 
sclerosis severity score
Fig. 5  Influence of MS susceptibility genotypes on MS duration 
in the Cardiff cohort. No significant difference in MS duration in 
patients with MS susceptibility SNP rs703842 (AG n = 36 and AA 
n = 35), compared to those without (GG n = 10; a). No significant dif-
ference in MS duration in patients heterozygous for MS susceptibil-
ity allele rs12368653 (AG = 44) but significantly shorter duration in 
homozygous patients (AA n = 11), compared to those without (GG 
n = 25; b). No significant difference in MS duration in patients with 
multiple copies of susceptibility SNPs rs703842 and rs12368653 
(AG/AG n = 24; AG/AA n = 20; AA/AA n = 11), compared to those 
without (GG/GG n = 10; GG/AG n = 12; c). Results expressed as 
median. Statistical test used: Kruskal–Wallis with post-hoc Dunn’s 
multiple comparison, *p < 0.05. AA homozygous adenine, A/G het-
erozygous adenine/guanine, GG homozygous guanine, MS multiple 
sclerosis
Fig. 6  MS susceptibility genotypes in relation to cohort relapse 
incidence in the Cardiff cohort (n = 62). Patients with copies of sus-
ceptibility SNPs (AG/AA) rs703842 (χ2 = 9.85, p < 0.01; a) and 
rs12368653 (χ2 = 9.93, p < 0.01; B) have documented relapses at time 
of lumbar puncture compared with patients who have no copies of 
the susceptibility alleles (GG). Statistical test used: Chi-square test, 
**p < 0.01. AA homozygous adenine, AG heterozygous adenine/gua-
nine, GG homozygous guanine
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transport; we have previously shown that nitric-oxide 
exposure reduces KIF5A expression in cultured neurons 
[33].
Other studies have highlighted that mutations in the 
KIF5A gene are directly linked to diseases with disturbed 
axonal transport and axonal loss [16–18]. GWAS have shown 
SNPs at chromosome 12q13–14 (which spans the KIF5A 
gene region), are linked to MS susceptibility [19–21]. Our 
previous human tissue studies have found significantly low-
ers levels of KIF5A in MS patients with copies of suscepti-
bility SNPs (rs12368653 and rs703842) that correlated with 
higher levels of dephosphorylated NFs, which are a hallmark 
of MS pathology [22, 23].
Results from our current study demonstrate CSF KIF5A 
levels are significantly different between patients heterozygous 
(AG) or homozygous (AA) for the rs703842 MS susceptibil-
ity allele. Data available from the 1000Genomes project has 
estimated the minor allele (G) frequency within a European 
population (sample size 1006) at 0.320. This may explain why 
significant differences were not detected in patients without the 
SNP (GG) compared with homozygotes (AA). The estimated 
minor allele (A) frequency for rs12368653 is 0.492. Patients 
homozygous for the rs12368653 adenine MS susceptibility 
allele had significantly shorter MS duration (time from docu-
mented symptom onset to LP), compared with patients with 
no copies. This may indicate that patients have a more aggres-
sive disease course, reaching diagnostic LP sooner. This theory 
is supported by additional findings from the Cardiff cohort 
which demonstrate that when genotype subsets (GG, AG, AA) 
are normalised to correct for allele population frequency, a 
higher percentage of patients with risk alleles (AG/AA) were 
in relapse at LP and went on to receive a DMT. Although of 
interest, it is important to note that the number of cases for 
rs703842 GG (n = 13) and rs12368653 AA (n = 18) were poten-
tially underpowered (n < 22); genotype findings would therefore 
need validation in larger cohort studies to compensate for the 
minor allele frequencies of both rs703842 and rs12368653 [34].
Both rs12368653 and rs703842 SNPs are upstream of 
the KIF5A gene and form part of a locus control region, 
comprising 17 candidate genes [20, 21]. As a result of link-
age disequilibrium, the non‐coding regions within several 
close genes can affect disease susceptibility and SNPs in 
non-protein coding regions can still affect gene splicing, 
transcription factor binding and mRNA degradation [20]. 
It is likely that the associations found with rs12368653 and 
rs703842 are not solely attributed to these individual SNPs 
and due to linkage disequilibrium, are linked with other 
SNPs around this gene locus at chromosome 12. Recent gene 
studies have indicated rs701006 as a lead MS susceptibil-
ity SNP within region 29 of chromosome 12 [35, 36]. In 
future studies it would be important to analyse this SNP and 
other recent candidate SNPs within the same region to assess 
whether individual or clusters of SNPs are linked with dis-
ease outcomes. This could also be expanded to incorporate 
an in silico analysis using RNA expression data from brain, 
available in public databases.
Overall, this study has shown quantifiable differences 
in CSF KIF5A levels between NINDC, CIS, RRMS and 
progressive MS, suggesting levels are predictive of MS. In 
addition, CSF KIF5A levels correlated with measures of MS 
disease severity in RRMS patients who were documented 
as having increased disability scores over 2-year follow-up, 
suggesting KIF5A may have future prognostic potential in 
predicting disease progression. Of interest, differences in 
CSF KIF5A levels were detected based on SNP rs703842, 
which is located at chromosome 12q13–14; a gene locus 
linked to MS susceptibility. SNP genotypes (rs703842 and 
rs12368653) alone showed differences with measures of MS 
disease activity, such as MS duration, proportion in relapse 
at the time of LP and DMT post LP. However, the findings 
require verification in a larger cohort and a full exploration 
of the prognostic value of all GWAS-identified MS suscep-
tibility SNPs within this gene locus.
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